Background: Among the kidney transplantation candidates, regardless if they already have a living related donor (LRD) or if they are waiting for a cadaveric donor (CD), the transplantation process is highly stressful, and the stress intensity is proportioned to the waiting time for surgery. The patients waiting for a CD have no certainty about receiving a kidney in time for surviving, or, when the patient's relatives refused the donation, they may feel rejected by their family. In chronic diseases, psychiatric comorbidity affects the disease evolution, dampering the treatment efficacy, leading to long-term hospitalizations and a more severe emotional stress.
Objective: To calculate the difference of anxiety and depression levels between LRD and CD patients.
Methods: The Hospital Anxiety and Depression scale (HAD) was applied to the kidney transplantation candidates who attended their first psychiatric evaluation along a year, they were grouped according to their kind of donor (LRD= 31, CD= 12). Statistical analysis was performed by means of Fisher and Mann-Whitney tests.
Results: 33.33% of the LRD patients were anxious (6.60+/- 2.65 points) and 40% were depressed (5.9+/- 3.29); 75% of the CD patients were anxious (p= 0.005) (10.17+/- 2.48, p< 0.001) and 90% were depressed (p= 0.088) (12.0+/- 9.33, p= 0.005).
Conclusions: The CD patients have a greater risk for anxiety and more severe depressive disorders than the LRD patients. Comparing this sample against 100 patients with chronic diseases, we found no differences with CD patients, but they have a higher risk for anxiety and depression than LRD patients, this may suggest that the last mentioned patients may overestimate the prognosis of their disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Estimating the Benefit of Transplant Over Dialysis in Candidates Over 55 Years.
Kidney360
January 2025
Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
Background: 'Life Years from Transplant' (LYFT) is a measure of the predicted difference between the expected lifespan with and without a kidney transplant. The metric was originally proposed in 1999; since then, demographics of the kidney transplant candidate population have materially changed.
Methods: Using contemporary SRTR data, we propose more sophisticated methods for estimating LYFT with a focus on older kidney transplant candidates, a growing sector of the current candidate pool.
WWC proteins-mediated compensatory mechanism restricts schwannomatosis driven by loss of function.
Sci Adv
January 2025
Institute of Pediatrics, Children's Hospital of Fudan University, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, State Key Laboratory of Genetic Engineering, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
NF2-related schwannomatosis, previously known as neurofibromatosis type 2, is a genetic disorder characterized by nerve tumors due to gene mutations. Mice with deletion develop schwannomas slowly with low penetrance, hence inconvenient for preclinical studies. Here, we show that NF2, by recruiting E3 ubiquitin ligases β-TrCP1/2, promotes WWC1-3 ubiquitination and degradation.
View Article and Find Full Text PDFFrailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care.
Front Immunol
January 2025
Institut Català d'Oncologia - Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
Introduction: This multicenter prospective study sponsored by the (GETH-TC) explores the use of frailty assessments in allo-HCT candidates.
Methods: Frailty was measured using the HCT Frailty Scale at first consultation and HCT admission in 404 adults from 15 HCT programs in Spain. Based on the results, patients were classified into fit, pre-frail and frail categories.
Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML.
Front Oncol
January 2025
BIOCEV, First Faculty of Medicine, Charles University, Prague, Czechia.
Introduction: Progressing myelodysplastic syndrome (MDS) into acute myeloid leukemia (AML) is an indication for hypomethylating therapy (HMA, 5-Azacytidine (AZA)) and a BCL2 inhibitor (Venetoclax, VEN) for intensive chemotherapy ineligible patients. Mouse models that engraft primary AML samples may further advance VEN + AZA resistance research.
Methods: We generated a set of transplantable murine PDX models from MDS/AML patients who developed resistance to VEN + AZA and compared the differences in hematopoiesis of the PDX models with primary bone marrow samples at the genetic level.
Endocannabinoid and hematological responses to pre- and post-therapeutic exercises in liver transplant patients.
Am J Clin Exp Immunol
December 2024
Medical Research Core Facility and Platforms, King Abdullah International Medical Research Centre, King Abdulaziz Medical City, Ministry of National Guard Health Affairs Riyadh, Saudi Arabia.
Endocannabinoids (eCBs) play a crucial role in regulating the pathophysiological progression of chronic liver disease through hepatic cannabinoid receptor 2 (CB2). According to the literature, various treatment options are available for liver disease patients, including transplantation and physical activity both before and after the procedure. The aim of this study is to assess the response of endocannabinoids to pre- and post-therapeutic exercises in liver transplant patients (LTx).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!